Skip to main
CELC
CELC logo

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity Inc. is advancing its clinical-stage therapeutic candidate, gedatolisib, a unique pan-PI3K and mTOR inhibitor, which has shown the potential for enhanced efficacy in patients with HR+/HER2- advanced breast cancer resistant to standard endocrine therapies. The company's ongoing Phase 3 trial, VIKTORIA-1, presents a promising opportunity for gedatolisib to achieve at least a three-month progression-free survival (PFS) improvement over existing treatments, thereby potentially obtaining a label for the wild-type population and enhancing market positioning. Historical data indicates that gedatolisib may outperform isoform-specific therapies in PIK3CA wild-type patients, contributing to a positive outlook for Celcuity's future performance in the biotechnology sector.

Bears say

Celcuity Inc reported no revenue for the period, alongside a net loss of $0.70 per diluted share, which was worse than the consensus estimate of a net loss of $0.65 per diluted share. The efficacy concerns regarding its lead therapeutic candidate, gedatolisib, are exacerbated by the high prevalence of ESR1 mutations in patients receiving fulvestrant, alongside significantly unfavorable progression-free survival rates in those who progress on frontline treatments. Additionally, the company faces challenges with poor oral bioavailability of its drug, necessitating intramuscular injections that may limit dose administration and overall treatment efficacy.

Celcuity (CELC) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.